Estramustine (BioDeep_00000008551)

 

Secondary id: BioDeep_00000858522

human metabolite blood metabolite Chemicals and Drugs


代谢物信息卡片


(1S,10R,11S,14S,15S)-14-hydroxy-15-methyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-2,4,6-trien-5-yl N,N-bis(2-chloroethyl)carbamate

化学式: C23H31Cl2NO3 (439.16808760000004)
中文名称: 雌莫司汀
谱图信息: 最多检出来源 Homo sapiens(blood) 31.16%

分子结构信息

SMILES: C1C(=CC2=C(C=1)[C@@]1([H])CC[C@]3(C)[C@@H](O)CC[C@@]3([H])[C@]1([H])CC2)OC(N(CCCl)CCCl)=O
InChI: InChI=1S/C23H31Cl2NO3/c1-23-9-8-18-17-5-3-16(29-22(28)26(12-10-24)13-11-25)14-15(17)2-4-19(18)20(23)6-7-21(23)27/h3,5,14,18-21,27H,2,4,6-13H2,1H3

描述信息

Estramustine is only found in individuals that have used or taken this drug. It is a nitrogen mustard linked to estradiol, usually as phosphate; used to treat prostatic neoplasms; also has radiation protective properties. [PubChem]Estramustine is a derivative of estradiol with a nitrogen mustard moiety. This gives it alkylating properties. In vivo, the nitrogen mustard component is active and can alklyate DNA and other cellular components (such as tubulin components) of rapidly dividing cells. This causes DNA strandbreaks or misscoding events. This leads to apoptosis and cell death. Also, due to the drugs estrogen component, it can bind more selectively to active estrogen receptors.
D000970 - Antineoplastic Agents > D018906 - Antineoplastic Agents, Alkylating > D009588 - Nitrogen Mustard Compounds
C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C2842 - DNA Binding Agent
C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C273 - Antimitotic Agent
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents
D009676 - Noxae > D000477 - Alkylating Agents
Same as: D04066

同义名列表

25 个代谢物同义名

(1S,10R,11S,14S,15S)-14-hydroxy-15-methyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-2,4,6-trien-5-yl N,N-bis(2-chloroethyl)carbamate; (17-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl) N,N-bis(2-chloroethyl)carbamate; estra-1,3,5(10)-triene-3,17beta-diol, 3-[bis(2-chloroethyl)carbamate]; 17beta-Estradiol 3-(bis(2-chloroethyl)carbamic acid); 17b-Estradiol 3-(bis(2-chloroethyl)carbamic acid); 17Β-estradiol 3-(bis(2-chloroethyl)carbamic acid); Estradiol 3-(N,N-bis(2-chloroethyl)carbamic acid); 17beta-Estradiol 3-(bis(2-chloroethyl)carbamate); 17Β-estradiol 3-(bis(2-chloroethyl)carbamate); Estradiol 3-(N,N-bis(2-chloroethyl)carbamate); 17b-Estradiol 3-(bis(2-chloroethyl)carbamate); Phosphate sodium, estramustine; Estramustine phosphate sodium; Estramustine sodium phosphate; Estramustin sodium phosphate; Phosphate, estramustin; Estramustin phosphate; Estramustinphosphate; Estramustinum; Estramustina; estramustine; Estracyt; Leo-275; Leo 275; Emcyt



数据库引用编号

18 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Clément Dumont, Giulia Baciarello, Pierre-Olivier Bosset, Pernelle Lavaud, Emeline Colomba, Christophe Massard, Yohann Loriot, Laurence Albiges, Pierre Blanchard, Alberto Bossi, Soazig Nenan, Karim Fizazi. Long-term Castration-related Outcomes in Patients With High-risk Localized Prostate Cancer Treated With Androgen Deprivation Therapy With or Without Docetaxel and Estramustine in the UNICANCER GETUG-12 Trial. Clinical genitourinary cancer. 2020 12; 18(6):444-451. doi: 10.1016/j.clgc.2020.03.017. [PMID: 32349927]
  • Vikram Patial, Supriya Sharma, Ugir Hossain Sk. Dendrimer conjugated estramustine nanocrystalline 'Dendot': An effective inhibitor of DMBA-TPA induced papilloma formation in mouse. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 2017 Nov; 109(?):316-323. doi: 10.1016/j.ejps.2017.08.026. [PMID: 28842350]
  • Atsushi Mizokami, Kouji Izumi, Hiroyuki Konaka, Yasuhide Kitagawa, Yoshifumi Kadono, Kazutaka Narimoto, Takahiro Nohara, Amit K Bahl, Mikio Namiki. Understanding prostate-specific antigen dynamics in monitoring metastatic castration-resistant prostate cancer: implications for clinical practice. Asian journal of andrology. 2017 Mar; 19(2):143-148. doi: 10.4103/1008-682x.179159. [PMID: 27270339]
  • Yasutomo Nakai, Kazuo Nishimura, Masashi Nakayama, Motohide Uemura, Hitoshi Takayama, Norio Nonomura, Akira Tsujimura. Weekly, low-dose docetaxel combined with estramustine for Japanese castration-resistant prostate cancer: its efficacy and safety profile compared with tri-weekly standard-dose treatment. International journal of clinical oncology. 2014 Feb; 19(1):165-72. doi: 10.1007/s10147-013-0536-7. [PMID: 23456140]
  • Kazuhiro Matsumoto, Nobuyuki Tanaka, Nozomi Hayakawa, Taisuke Ezaki, Kenjiro Suzuki, Takahiro Maeda, Akiharu Ninomiya, So Nakamura. Efficacy of estramustine phosphate sodium hydrate (EMP) monotherapy in castration-resistant prostate cancer patients: report of 102 cases and review of literature. Medical oncology (Northwood, London, England). 2013 Dec; 30(4):717. doi: 10.1007/s12032-013-0717-2. [PMID: 24005812]
  • Ugir Hossain Sk, Deobrat Dixit, Ellora Sen. Comparative study of microtubule inhibitors--estramustine and natural podophyllotoxin conjugated PAMAM dendrimer on glioma cell proliferation. European journal of medicinal chemistry. 2013 Oct; 68(?):47-57. doi: 10.1016/j.ejmech.2013.07.007. [PMID: 23954240]
  • Jody T Mack, Carol B Brown, Tracy E Garrett, Joachim D Uys, Danyelle M Townsend, Kenneth D Tew. Ablation of the ATP-binding cassette transporter, Abca2 modifies response to estrogen-based therapies. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2012 Sep; 66(6):403-8. doi: 10.1016/j.biopha.2012.06.007. [PMID: 22898081]
  • Shintaro Narita, Norihiko Tsuchiya, Takeshi Yuasa, Shinya Maita, Takashi Obara, Kazuyuki Numakura, Hiroshi Tsuruta, Mitsuru Saito, Takamitsu Inoue, Yohei Horikawa, Shigeru Satoh, Tomonori Habuchi. Outcome, clinical prognostic factors and genetic predictors of adverse reactions of intermittent combination chemotherapy with docetaxel, estramustine phosphate and carboplatin for castration-resistant prostate cancer. International journal of clinical oncology. 2012 Jun; 17(3):204-11. doi: 10.1007/s10147-011-0275-6. [PMID: 21706123]
  • Masayoshi Zaitsu, Mariko Yamanoi, Koji Mikami, Yuta Takeshima, Naohiko Okamoto, Sadao Imao, Akiko Tonooka, Takumi Takeuchi. Surgical castration in hormone-refractory metastatic prostate cancer patients can be an alternative for medical castration. Advances in urology. 2012; 2012(?):979154. doi: 10.1155/2012/979154. [PMID: 21754927]
  • Yasuhiro Hashimoto, Kengo Imanishi, Akiko Okamoto, Atsushi Sasaki, Hisao Saitoh, Ryuichi Wada, Hayato Yamamoto, Takuya Koie, Chikara Ohyama. An aggressive signet ring cell carcinoma of the prostate in a Japanese man. Case reports in oncology. 2011 Sep; 4(3):517-20. doi: 10.1159/000334081. [PMID: 22114579]
  • Glenn Tisman, April Garcia. Control of prostate cancer associated with withdrawal of a supplement containing folic acid, L-methyltetrahydrofolate and vitamin B12: a case report. Journal of medical case reports. 2011 Aug; 5(?):413. doi: 10.1186/1752-1947-5-413. [PMID: 21867542]
  • Yoshiki Hiyama, Hiroshi Kitamura, Satoshi Takahashi, Naoya Masumori, Tetsuya Shindo, Mitsuhiro Tsujiwaki, Tomoko Mitsuhashi, Tadashi Hasegawa, Taiji Tsukamoto. Peritoneal dissemination of prostate cancer due to laparoscopic radical prostatectomy: a case report. Journal of medical case reports. 2011 Aug; 5(?):355. doi: 10.1186/1752-1947-5-355. [PMID: 21819588]
  • Joon Il Choi, Yun Beom Kim, Seung Ok Yang, Jeong Kee Lee, Tae Young Jung. Efficacy of alternative antiandrogen therapy for prostate cancer that relapsed after initial maximum androgen blockade. Korean journal of urology. 2011 Jul; 52(7):461-5. doi: 10.4111/kju.2011.52.7.461. [PMID: 21860766]
  • Jae-Lyun Lee, Jeong Eun Kim, Jin-Hee Ahn, Dae-Ho Lee, Junghsin Lee, Choung-Soo Kim, Jun Hyuk Hong, Bumsik Hong, Cheryn Song, Hanjong Ahn. Role of androgen deprivation treatment in patients with castration-resistant prostate cancer, receiving docetaxel-based chemotherapy. American journal of clinical oncology. 2011 Apr; 34(2):140-4. doi: 10.1097/coc.0b013e3181d2ed7d. [PMID: 20686407]
  • Yukiyoshi Hirayama, Yoshihiro Ito, Tomohiro Kanamaru, Teppei Sonoda, Masato Aoyama, Norihiro Nakamura, Masaki Kawamura. [A case of castration-refractory prostate cancer showing marked decrease of serum PSA level after zoledronic acid treatment with estramustine phosphate and prednisolone]. Gan to kagaku ryoho. Cancer & chemotherapy. 2011 Mar; 38(3):485-7. doi: NULL. [PMID: 21403461]
  • Clara Hwang, Elisabeth I Heath. Angiogenesis inhibitors in the treatment of prostate cancer. Journal of hematology & oncology. 2010 Aug; 3(?):26. doi: 10.1186/1756-8722-3-26. [PMID: 20678204]
  • Yoshihiro Nakagami, Makoto Ohori, Noboru Sakamoto, Shoji Koga, Riu Hamada, Tadashi Hatano, Masaaki Tachibana. Safety and efficacy of docetaxel, estramustine phosphate and hydrocortisone in hormone-refractory prostate cancer patients. International journal of urology : official journal of the Japanese Urological Association. 2010 Jul; 17(7):629-34. doi: 10.1111/j.1442-2042.2010.02544.x. [PMID: 20438593]
  • Tomihiko Yasufuku, Katsumi Shigemura, Osamu Matsumoto, Soichi Arakawa, Masato Fujisawa. Combination chemotherapy with weekly paclitaxel or docetaxel, carboplatin, and estramustine for hormone-refractory prostate cancer. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy. 2010 Jun; 16(3):200-5. doi: 10.1007/s10156-010-0047-7. [PMID: 20221782]
  • Yoshitatsu Sei, Zhen Li, Jian Song, Renee Ren-Patterson, Elizabeth M Tunbridge, Yukihiko Iizuka, Masahiro Inoue, Berenice T Alfonso, Senda Beltaifa, Yoko Nakai, Bhaskar S Kolachana, Jingshan Chen, Daniel R Weinberger. Epistatic and functional interactions of catechol-o-methyltransferase (COMT) and AKT1 on neuregulin1-ErbB signaling in cell models. PloS one. 2010 May; 5(5):e10789. doi: 10.1371/journal.pone.0010789. [PMID: 20520724]
  • Paul G Corn, Timothy C Thompson. Identification of a novel prostate cancer biomarker, caveolin-1: Implications and potential clinical benefit. Cancer management and research. 2010 May; 2(?):111-22. doi: 10.2147/cmar.s9835. [PMID: 21188102]
  • George P Stathopoulos, John Koutantos, Michael M Vaslamatzis, Athanasios Athanasiadis, George Papadopoulos, G Labrodimou, John Stathopoulos, Sotiris Rigatos. Survival after cytotoxic chemotherapy in patients with advanced hormone-resistant prostate cancer: a phase II study. Oncology reports. 2009 Aug; 22(2):345-8. doi: . [PMID: 19578775]
  • T Koreckij, H Nguyen, L G Brown, E Y Yu, R L Vessella, E Corey. Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis. British journal of cancer. 2009 Jul; 101(2):263-8. doi: 10.1038/sj.bjc.6605178. [PMID: 19603032]
  • Y Loriot, C Massard, M Gross-Goupil, M Di Palma, B Escudier, A Bossi, K Fizazi. Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features. Annals of oncology : official journal of the European Society for Medical Oncology. 2009 Apr; 20(4):703-8. doi: 10.1093/annonc/mdn694. [PMID: 19179557]
  • Taku Naiki, Takehiko Okamura, Noriyasu Kawai, Hiroshi Sakagami, Yasuyuki Yamada, Keiji Fujita, Hidetoshi Akita, Yoshihiro Hashimoto, Keiichi Tozawa, Kenjiro Kohri. Advantages of second line estramustine for overall survival of hormone-refractory prostate cancer (HRPC) patients. Asian Pacific journal of cancer prevention : APJCP. 2009 Jan; 10(1):71-4. doi: . [PMID: 19469628]
  • R Thuret, C Massard, M Gross-Goupil, B Escudier, M Di Palma, A Bossi, R de Crevoisier, A Chauchereau, K Fizazi. The postchemotherapy PSA surge syndrome. Annals of oncology : official journal of the European Society for Medical Oncology. 2008 Jul; 19(7):1308-1311. doi: 10.1093/annonc/mdn062. [PMID: 18356135]
  • Shuichiro Kobayashi, Tetsuro Tsukamoto, Akira Tohsaka, Tsuguhiro Tohma. [Estramustine phosphate withdrawal syndrome in relapsed prostate cancer: two case reports]. Hinyokika kiyo. Acta urologica Japonica. 2008 Jun; 54(6):423-6. doi: . [PMID: 18634439]
  • Y Yamada, S Takahashi, T Fujimura, H Nishimatsu, A Ishikawa, H Kume, K Tomita, T Takeuchi, T Kitamura. The effect of combined androgen blockade on bone turnover and bone mineral density in men with prostate cancer. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2008 Mar; 19(3):321-7. doi: 10.1007/s00198-007-0472-3. [PMID: 17906826]
  • Atsushi Takenaka, Yuji Yamada, Toshifumi Kurahashi, Hideo Soga, Hideaki Miyake, Masato Fujisawa. Combination chemotherapy with weekly docetaxel and estramustine for hormone refractory prostate cancer in Japanese patients. International journal of urology : official journal of the Japanese Urological Association. 2008 Jan; 15(1):106-9. doi: 10.1111/j.1442-2042.2007.01929.x. [PMID: 18184188]
  • Karim Fizazi, Aurelie Le Maitre, Gary Hudes, William R Berry, W Kevin Kelly, Jean-Christophe Eymard, Christopher J Logothetis, Jean-Pierre Pignon, Stefan Michiels. Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data. The Lancet. Oncology. 2007 Nov; 8(11):994-1000. doi: 10.1016/s1470-2045(07)70284-x. [PMID: 17942366]
  • Patricia Puig, F W Alexander Tempels, Francesc Borrull, Marta Calull, Carme Aguilar, Govert W Somsen, Gerhardus J de Jong. On-line coupling of solid-phase extraction and capillary electrophoresis for the determination of cefoperazone and ceftiofur in plasma. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2007 Sep; 856(1-2):365-70. doi: 10.1016/j.jchromb.2007.05.030. [PMID: 17572160]
  • Takahiko Sakuma, Takahiro Yoshida, Hiroshi Ohashi, Kensaku Nishimura, Kiyoshi Kawano. [Prostatic carcinoma that arose with hearing loss: a case report]. Hinyokika kiyo. Acta urologica Japonica. 2007 Jun; 53(6):413-6. doi: . [PMID: 17628942]
  • Hideyuki Akaza, Malcolm A Moore, Shu-Jen Chang, Christopher Cheng, Han Yong Choi, Kesavan Esuvaranathan, Shiro Hinotsu, Sung-Joon Hong, Choung-Soo Kim, Wun-Jae Kim, Masaru Murai, Seiji Naito, Doddy Soebadi, Jae-Mann Song, Rainy Umbas, Michiyuki Usami, Shujie Xia, Chi-Rei Yang. The 5th Conference on Asian Trends in Prostate Cancer Hormone Therapy. Asian Pacific journal of cancer prevention : APJCP. 2007 Jan; 8(1):3-12. doi: NULL. [PMID: 17477764]
  • Kyogo Itoh, Akira Yamada. Personalized peptide vaccines: a new therapeutic modality for cancer. Cancer science. 2006 Oct; 97(10):970-6. doi: 10.1111/j.1349-7006.2006.00272.x. [PMID: 16984371]
  • G Kramer, S Schwarz, M Hägg, A Mandic Havelka, S Linder. Docetaxel induces apoptosis in hormone refractory prostate carcinomas during multiple treatment cycles. British journal of cancer. 2006 Jun; 94(11):1592-8. doi: 10.1038/sj.bjc.6603129. [PMID: 16685278]
  • John D Hainsworth, Anthony A Meluch, David R Spigel, Kathleen Yost, Christina Meng, F Anthony Greco. Weekly docetaxel/estramustine phosphate in patients with increasing serum prostate- specific antigen levels after primary treatment for prostate cancer: a phase II trial of the Minnie Pearl Cancer Research Network. Clinical genitourinary cancer. 2006 Mar; 4(4):287-92. doi: 10.3816/cgc.2006.n.009. [PMID: 16729913]
  • Angela Boehmer, Aristotelis G Anastasiadis, Susan Feyerabend, Udo Nagele, Markus Kuczyk, David Schilling, Stefan Corvin, Axel S Merseburger, Arnulf Stenzl. Docetaxel, estramustine and prednisone for hormone-refractory prostate cancer: a single-center experience. Anticancer research. 2005 Nov; 25(6C):4481-6. doi: NULL. [PMID: 16334130]
  • Atsuro Sawada, Takehiko Segawa, Shinichi Nakanishi, Hidefumi Kinoshita, Shingo Yamamoto, Toshiyuki Kamoto, Osamu Ogawa. [Prostate cancer with penile metastasis: a case report]. Hinyokika kiyo. Acta urologica Japonica. 2005 Nov; 51(11):771-3. doi: NULL. [PMID: 16363713]
  • Takehiko Segawa, Toshiyuki Kamoto, Hidefumi Kinoshita, Yasuharu Kunishima, Koji Yoshimura, Akihiro Ito, Takeshi Takahashi, Shin Higashi, Eijiro Nakamura, Hirofumi Nishiyama, Noriyuki Ito, Shingo Yamamoto, Tomonori Habuchi, Osamu Ogawa. Monthly paclitaxel and carboplatin with oral estramustine phosphate in patients with hormone-refractory prostate cancer. International journal of clinical oncology. 2005 Oct; 10(5):333-7. doi: 10.1007/s10147-005-0513-x. [PMID: 16247660]
  • A Berruti, M Tucci, A Mosca, R Tarabuzzi, G Gorzegno, C Terrone, F Vana, G Lamanna, M Tampellini, F Porpiglia, A Angeli, R M Scarpa, L Dogliotti. Predictive factors for skeletal complications in hormone-refractory prostate cancer patients with metastatic bone disease. British journal of cancer. 2005 Sep; 93(6):633-8. doi: 10.1038/sj.bjc.6602767. [PMID: 16222309]
  • Georgios Fotios Samelis, Haralambos Kalofonos, Adamos Adamou, Paris Kosmides, Dimosthenis Skarlos, Gerasimos Aravantinos, Christos Kiamouris, Oneynadum Adimchi, Georgios Fountzilas, Athanasios Meletios Dimopoulos. The combination of estramustine, vinorelbine, and mitoxantrone in hormone-refractory prostate cancer: a Phase II feasibility study conducted by the Hellenic Cooperative Oncology Group. Urology. 2005 Aug; 66(2):382-5. doi: 10.1016/j.urology.2005.02.023. [PMID: 16098366]
  • Masanori Noguchi, Kyogo Itoh, Akihisa Yao, Takashi Mine, Akira Yamada, Yayoi Obata, Masatoshi Furuta, Mamoru Harada, Shigetaka Suekane, Kei Matsuoka. Immunological evaluation of individualized peptide vaccination with a low dose of estramustine for HLA-A24+ HRPC patients. The Prostate. 2005 Apr; 63(1):1-12. doi: 10.1002/pros.20157. [PMID: 15378520]
  • Sheila A Doggrell. Which drug combination for hormone-refractory prostate cancer?. Expert opinion on pharmacotherapy. 2005 Apr; 6(4):667-70. doi: 10.1517/14656566.6.4.667. [PMID: 15934892]
  • Teodoro Sava, Umberto Basso, Antonio Porcaro, Gian Luigi Cetto. New standards in the chemotherapy of metastatic hormone-refractory prostate cancer. Expert review of anticancer therapy. 2005 Feb; 5(1):53-62. doi: 10.1586/14737140.5.1.53. [PMID: 15757438]
  • Daisaku Hirano, Sadatsugu Minei, Yuichi Kishimoto, Kenya Yamaguchi, Takahiko Hachiya, Toshio Yoshida, Tetsuo Yoshikawa, Makoto Endoh, Yataroh Yamanaka, Tadao Yamamoto, Yasuo Satoh, Hajime Ishida, Kiyoki Okada, Yukie Takimoto. Prospective study of estramustine phosphate for hormone refractory prostate cancer patients following androgen deprivation therapy. Urologia internationalis. 2005; 75(1):43-9. doi: 10.1159/000085926. [PMID: 16037707]
  • Costantino Cerulli, Alessandro Sciarra, Gianfilippo Salvatori, Franco Di Silverio. Long-term response to combination therapy with estramustine and somatostatin analogue in a patient with androgen ablation-refractory prostate cancer. Urology. 2004 Dec; 64(6):1231.e1-3. doi: 10.1016/j.urology.2004.06.066. [PMID: 15596212]
  • Daniel P Petrylak, Catherine M Tangen, Maha H A Hussain, Primo N Lara, Jeffrey A Jones, Mary Ellen Taplin, Patrick A Burch, Donna Berry, Carol Moinpour, Manish Kohli, Mitchell C Benson, Eric J Small, Derek Raghavan, E David Crawford. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. The New England journal of medicine. 2004 Oct; 351(15):1513-20. doi: 10.1056/nejmoa041318. [PMID: 15470214]
  • A Nicolini, Pa Mancini, P Ferrari, L Anselmi, G Tartarelli, V Bonazzi, A Carpi, R Giardino. Oral low-dose cyclophosphamide in metastatic hormone refractory prostate cancer (MHRPC). Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2004 Oct; 58(8):447-50. doi: 10.1016/j.biopha.2004.08.006. [PMID: 15464874]
  • Toru Kanno, Noboru Shibasaki, Yutaka Tsuji, Yoji Taki, Hideo Takeuchi. [Combination therapy with estramustine and docetaxel for hormone refractory prostate cancer]. Hinyokika kiyo. Acta urologica Japonica. 2004 Aug; 50(8):521-4. doi: . [PMID: 15471069]
  • Masanori Noguchi, Kyogo Itoh, Shigetaka Suekane, Akiko Morinaga, Aki Sukehiro, Norie Suetsugu, Kazuko Katagiri, Akira Yamada, Shinshi Noda. Immunological monitoring during combination of patient-oriented peptide vaccination and estramustine phosphate in patients with metastatic hormone refractory prostate cancer. The Prostate. 2004 Jun; 60(1):32-45. doi: 10.1002/pros.20011. [PMID: 15129427]
  • M Breda, G Basileo, C A James. Simultaneous determination of estramustine phosphate and its four metabolites in human plasma by liquid chromatography-ionspray mass spectrometry. Biomedical chromatography : BMC. 2004 Jun; 18(5):293-301. doi: 10.1002/bmc.319. [PMID: 15236437]
  • Uta Schmidt, Udo Bilkenroth, Clemens Linné, Susanne Fuessel, Kai Kraemer, Michael Froehner, Manfred P Wirth, Axel Meye. Quantification of disseminated tumor cells in the bloodstream of patients with hormone-refractory prostate carcinoma undergoing cytotoxic chemotherapy. International journal of oncology. 2004 Jun; 24(6):1393-9. doi: NULL. [PMID: 15138579]
  • R Morant, J Bernhard, D Dietrich, S Gillessen, M Bonomo, M Borner, J Bauer, T Cerny, C Rochlitz, M Wernli, A Gschwend, S Hanselmann, F Hering, H-P Schmid. Capecitabine in hormone-resistant metastatic prostatic carcinoma - a phase II trial. British journal of cancer. 2004 Apr; 90(7):1312-7. doi: 10.1038/sj.bjc.6601673. [PMID: 15054447]
  • Takahiro Kojima, Toru Shimazui, Mizuki Onozawa, Sadamu Tsukamoto, Shiro Hinotsu, Naoto Miyanaga, Kazunori Hattori, Koji Kawai, Hideyuki Akaza. Weekly administration of docetaxel in patients with hormone-refractory prostate cancer: a pilot study on Japanese patients. Japanese journal of clinical oncology. 2004 Mar; 34(3):137-41. doi: 10.1093/jjco/hyh021. [PMID: 15078909]
  • Shuk-Mei Ho. Estrogens and anti-estrogens: key mediators of prostate carcinogenesis and new therapeutic candidates. Journal of cellular biochemistry. 2004 Feb; 91(3):491-503. doi: 10.1002/jcb.10759. [PMID: 14755680]
  • Badrinath R Konety, James A Eastham, Vicor E Reuter, Peter T Scardino, S Machele Donat, Guido Dalbagni, Paul Russo, Harry W Herr, Larry Schwartz, Philip W Kantoff, Howard Scher, W Kevin Kelly. Feasibility of radical prostatectomy after neoadjuvant chemohormonal therapy for patients with high risk or locally advanced prostate cancer: results of a phase I/II study. The Journal of urology. 2004 Feb; 171(2 Pt 1):709-13. doi: 10.1097/01.ju.0000108122.36893.5a. [PMID: 14713792]
  • Masanori Noguchi, Shinshi Noda, Masaki Yoshida, Shoichi Ueda, Taizo Shiraishi, Kyogo Itoh. Chemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist. International journal of urology : official journal of the Japanese Urological Association. 2004 Feb; 11(2):103-9. doi: 10.1111/j.1442-2042.2004.t01-1-00748.x. [PMID: 14706014]
  • James A Eastham, William K Kelly, Gary D Grossfeld, Eric J Small. Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease. Urology. 2003 Dec; 62 Suppl 1(?):55-62. doi: 10.1016/j.urology.2003.09.052. [PMID: 14747042]
  • William K Oh. The evolving role of chemotherapy and other systemic therapies for managing localized prostate cancer. The Journal of urology. 2003 Dec; 170(6 Pt 2):S28-32; discussion S33. doi: 10.1097/01.ju.0000095356.02647.64. [PMID: 14610407]
  • Naomi B Haas, Bruce J Giantonio, Samuel Litwin, Carl J Minniti, Stephen Fox, Gwen Yeslow, Robert Reilly, Kenneth Nahum, Richard Greenberg, Theresa Halbherr, Gary R Hudes. Vinblastine and estramustine phosphate in metastatic renal cell carcinoma: a phase II trial of the Fox Chase Network. Cancer. 2003 Nov; 98(9):1837-41. doi: 10.1002/cncr.11734. [PMID: 14584064]
  • T M Beer, M Garzotto, W D Henner, K M Eilers, E M Wersinger. Intermittent chemotherapy in metastatic androgen-independent prostate cancer. British journal of cancer. 2003 Sep; 89(6):968-70. doi: 10.1038/sj.bjc.6601232. [PMID: 12966410]
  • William Kevin Kelly, Andrew X Zhu, Howard Scher, Tracey Curley, Mary Fallon, Susan Slovin, Lawrence Schwartz, Steve Larson, William Tong, Beryl Hartley-Asp, Cinzia Pellizzoni, Maurizio Rocchetti. Dose escalation study of intravenous estramustine phosphate in combination with Paclitaxel and Carboplatin in patients with advanced prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2003 Jun; 9(6):2098-107. doi: NULL. [PMID: 12796374]
  • G F Samelis, D Skarlos, D Bafaloukos, P Kosmidis, A Anagnostopoulos, G Aravantinos, M A Dimopoulos. The combination of estramustine and mitoxantrone in hormone-refractory prostate cancer: a phase II feasibility study conducted by the Hellenic Cooperative Oncology Group. Urology. 2003 Jun; 61(6):1211-5. doi: 10.1016/s0090-4295(03)00019-0. [PMID: 12809899]
  • Kazuo Nishimura, Yasutomo Nakai, Kiyonori Shimizu, Takashi Tokizane, Yasuyuki Arai, Hitoshi Inoue, Natsuki Takaha, Norio Nonomura, Akihiko Okuyama, Kazumi Kamoi, Osamu Ukimura, Tsuneharu Miki, Takuo Koide, Yasuji Ichikawa, Kenji Nishimura, Hideki Sugao, Seiji Yamaguchi, Hiroshi Takatera, Kinya Uchida, Hidenobu Miura. [Hormonal chemotherapy for hormone-refractory prostate cancer]. Hinyokika kiyo. Acta urologica Japonica. 2002 Nov; 48(11):713-8. doi: NULL. [PMID: 12512147]
  • Christopher J Logothetis. Docetaxel in the integrated management of prostate cancer. Current applications and future promise. Oncology (Williston Park, N.Y.). 2002 Jun; 16(6 Suppl 6):63-72. doi: NULL. [PMID: 12108899]
  • Wallace Akerley, James Butera, Terek Wehbe, Richard Noto, Barry Stein, Howard Safran, Frank Cummings, Sundaresan Sambandam, John Maynard, Gregory Di Rienzo, Louis Leone. A multiinstitutional, concurrent chemoradiation trial of strontium-89, estramustine, and vinblastine for hormone refractory prostate carcinoma involving bone. Cancer. 2002 Mar; 94(6):1654-60. doi: 10.1002/cncr.10437. [PMID: 11920525]
  • Gary Hudes, Naomi Haas, Gwen Yeslow, Thomas Gillon, Per Olov Gunnarsson, Marianne Ellman, Orjan Nordle, Brigitta Eriksson, Langdon Miller, Laura Cisar, Michael Kopreski, Donatella Viaro, Beryl Hartley-Asp. Phase I clinical and pharmacologic trial of intravenous estramustine phosphate. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2002 Feb; 20(4):1115-27. doi: 10.1200/jco.2002.20.4.1115. [PMID: 11844837]
  • Rob C M Pelger, Guus A B Lycklama A Nijeholt, Aielko H Zwinderman, Neveen A T Hamdy. The flare in alkaline phosphatase activity post-orchidectomy predicts which patient may benefit from early chemotherapy in metastatic prostate cancer. The Prostate. 2002 Feb; 50(2):119-24. doi: 10.1002/pros.10040. [PMID: 11816020]
  • Gunnar Steineck, Victor Reuter, William K Kelly, Richard Frank, Larry Schwartz, Howard I Scher. Cytotoxic treatment of aggressive prostate tumors with or without neuroendocrine elements. Acta oncologica (Stockholm, Sweden). 2002; 41(7-8):668-74. doi: 10.1080/028418602321028292. [PMID: 14651212]
  • S Saito, J Nakashima, Y Nakajima, K Ikeuchi, T Shibayama, K Nagakura, Y Naide, M Hayakawa, Y Ogawa, M Hata, M Nakazono, S Hasegawa, T Oda, S Kimura, S Nakamura, J Matsunaga, T Fujioka, H Tanoguchi, S Aoki, Y Yamamoto, A Izawa, S Kimura, K Suzuki, H Tazaki, M Murai. [Clinical efficacy of leuprolide acetate and combined treatment with estramustine for advanced prostate cancer]. Nihon Hinyokika Gakkai zasshi. The japanese journal of urology. 2001 Nov; 92(7):682-93. doi: 10.5980/jpnjurol1989.92.682. [PMID: 11766367]
  • A Emoto, N Nasu, H Mimata, Y Nomura, H Mizokuchi, M Wada. [A male case of primary bilateral breast cancers during estrogen therapy for prostate cancer]. Nihon Hinyokika Gakkai zasshi. The japanese journal of urology. 2001 Nov; 92(7):698-701. doi: 10.5980/jpnjurol1989.92.698. [PMID: 11766369]
  • M Sitka Copur, P Ledakis, J Lynch, R Hauke, S Tarantolo, M Bolton, M Norvell, J Muhvic, L Hake, J Wendt. Weekly docetaxel and estramustine in patients with hormone-refractory prostate cancer. Seminars in oncology. 2001 Aug; 28(4 Suppl 15):16-21. doi: 10.1016/s0093-7754(01)90150-2. [PMID: 11685724]
  • D S Park, R Vassilopoulou Sellin, S Tu. Estramustine-related hypocalcemia in patients with prostate carcinoma and osteoblastic metastases. Urology. 2001 Jul; 58(1):105. doi: 10.1016/s0090-4295(01)01119-0. [PMID: 11445494]
  • A C Ferrari, A Chachoua, H Singh, M Rosenthal, S Taneja, M Bednar, J Mandeli, F Muggia. A Phase I/II study of weekly paclitaxel and 3 days of high dose oral estramustine in patients with hormone-refractory prostate carcinoma. Cancer. 2001 Jun; 91(11):2039-45. doi: 10.1002/1097-0142(20010601)91:11<2039::aid-cncr1230>3.0.co;2-r. [PMID: 11391583]
  • H G Munshi, K J Pienta, D C Smith. Chemotherapy in patients with prostate specific antigen-only disease after primary therapy for prostate carcinoma: a phase II trial of oral estramustine and oral etoposide. Cancer. 2001 Jun; 91(11):2175-80. doi: 10.1002/1097-0142(20010601)91:11<2175::aid-cncr1246>3.0.co;2-d. [PMID: 11391599]
  • M Zaky Ahel, K Kovacic, I Kraljic, M Tarle. Oral estramustine therapy in serum chromogranin A-positive stage D3 prostate cancer patients. Anticancer research. 2001 Mar; 21(2B):1475-9. doi: . [PMID: 11396235]
  • E Ben-Josef, A T Porter, S Han, W Mertens, P Chuba, J Fontana, M Hussain. Neoadjuvant estramustine and etoposide followed by concurrent estramustine and definitive radiotherapy for locally advanced prostate cancer: feasibility and preliminary results. International journal of radiation oncology, biology, physics. 2001 Mar; 49(3):699-703. doi: 10.1016/s0360-3016(00)01375-4. [PMID: 11172951]
  • S M Tu, R E Millikan, B Mengistu, E S Delpassand, R J Amato, L C Pagliaro, D Daliani, C N Papandreou, T L Smith, J Kim, D A Podoloff, C J Logothetis. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet (London, England). 2001 Feb; 357(9253):336-41. doi: 10.1016/s0140-6736(00)03639-4. [PMID: 11210994]
  • T Kitamura. Necessity of re-evaluation of estramustine phosphate sodium (EMP) as a treatment option for first-line monotherapy in advanced prostate cancer. International journal of urology : official journal of the Japanese Urological Association. 2001 Feb; 8(2):33-6. doi: 10.1046/j.1442-2042.2001.00254.x. [PMID: 11240822]
  • P E Clark, D M Peereboom, R Dreicer, H S Levin, S B Clark, E A Klein. Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer. Urology. 2001 Feb; 57(2):281-5. doi: 10.1016/s0090-4295(00)00914-6. [PMID: 11182337]
  • W K Kelly, T Curley, S Slovin, G Heller, J McCaffrey, D Bajorin, A Ciolino, K Regan, M Schwartz, P Kantoff, D George, W Oh, M Smith, D Kaufman, E J Small, L Schwartz, S Larson, W Tong, H Scher. Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2001 Jan; 19(1):44-53. doi: 10.1200/jco.2001.19.1.44. [PMID: 11134194]
  • M J Haut, J F Harryhill, J Rosenstock, M J Warhol, R Vitti. Progressing prostate carcinoma. The oncologist. 2001; 6(2):183-96. doi: 10.1634/theoncologist.6-2-183. [PMID: 11306730]
  • D Daliani. Development of angiogenesis inhibition as therapy for prostate cancer. Oncology (Williston Park, N.Y.). 2000 Dec; 14(12 Suppl 13):21-3. doi: . [PMID: 11204669]
  • M R Smith, D Kaufman, W Oh, K Guerin, M Seiden, T Makatsoris, J Manola, P W Kantoff. Vinorelbine and estramustine in androgen-independent metastatic prostate cancer: a phase II study. Cancer. 2000 Oct; 89(8):1824-8. doi: 10.1002/1097-0142(20001015)89:8<1824::aid-cncr24>3.0.co;2-r. [PMID: 11042579]
  • M Edgren, B Lennernäs. Estramustine a radio sensitising agent. Anticancer research. 2000 Jul; 20(4):2677-80. doi: NULL. [PMID: 10953342]
  • M J Zelefsky, W K Kelly, H I Scher, H Lee, T Smart, E Metz, L Schwartz, Z Fuks, S A Leibel. Results of a phase II study using estramustine phosphate and vinblastine in combination with high-dose three-dimensional conformal radiotherapy for patients with locally advanced prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2000 May; 18(9):1936-41. doi: 10.1200/jco.2000.18.9.1936. [PMID: 10784635]
  • A L Weitzman, G Shelton, N Zuech, C E Owen, T Judge, M Benson, I Sawczuk, A Katz, C A Olsson, E Bagiella, C Pfaff, J H Newhouse, D P Petrylak. Dexamethasone does not significantly contribute to the response rate of docetaxel and estramustine in androgen independent prostate cancer. The Journal of urology. 2000 Mar; 163(3):834-7. doi: NULL. [PMID: 10687988]
  • K Edman, L Svensson, B Eriksson, P O Gunnarsson. Determination of estramustine phosphate and its metabolites estromustine, estramustine, estrone and estradiol in human plasma by liquid chromatography with fluorescence detection and gas chromatography with nitrogen-phosphorus and mass spectrometric detection. Journal of chromatography. B, Biomedical sciences and applications. 2000 Feb; 738(2):267-79. doi: 10.1016/s0378-4347(99)00526-5. [PMID: 10718645]
  • B J Roth. Androgen-independent prostate cancer: not so chemorefractory after all. Seminars in oncology. 1999 Dec; 26(6 Suppl 18):43-50. doi: NULL. [PMID: 10892577]
  • D P Petrylak, R B Macarthur, J O'Connor, G Shelton, T Judge, J Balog, C Pfaff, E Bagiella, D Heitjan, R Fine, N Zuech, I Sawczuk, M Benson, C A Olsson. Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1999 Mar; 17(3):958-67. doi: 10.1200/jco.1999.17.3.958. [PMID: 10071290]
  • S Tsukamoto, H Akaza. [Progress in oral anti-cancer drug therapy for urological cancer]. Gan to kagaku ryoho. Cancer & chemotherapy. 1999 Feb; 26(3):308-14. doi: NULL. [PMID: 10065093]
  • S Culine, J Kattan, S Zanetta, C Théodore, K Fizazi, J P Droz. Evaluation of estramustine phosphate combined with weekly doxorubicin in patients with androgen-independent prostate cancer. American journal of clinical oncology. 1998 Oct; 21(5):470-4. doi: 10.1097/00000421-199810000-00010. [PMID: 9781602]
  • P H Walz, P Björk, P O Gunnarsson, K Edman, B Hartley-Asp. Differential uptake of estramustine phosphate metabolites and its correlation with the levels of estramustine binding protein in prostate tumor tissue. Clinical cancer research : an official journal of the American Association for Cancer Research. 1998 Sep; 4(9):2079-84. doi: NULL. [PMID: 9748122]
  • D C Smith, R L Dunn, M S Strawderman, K J Pienta. Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1998 May; 16(5):1835-43. doi: 10.1200/jco.1998.16.5.1835. [PMID: 9586898]
  • M Johansson, A T Bergenheim, R D'Argy, K Edman, P O Gunnarsson, A Widmark, R Henriksson. Distribution of estramustine in the BT4C rat glioma model. Cancer chemotherapy and pharmacology. 1998; 41(4):317-25. doi: 10.1007/s002800050745. [PMID: 9488601]
  • H Shiina, M Igawa, K Shigeno, Y Wada, T Yoneda, H Yagi, R Shirakawa, M Nagasaki. Relationship of serum testosterone level with proliferating cell nuclear antigen and nm23 protein in human prostatic carcinoma tissue. Oncology. 1997 Nov; 54(6):482-9. doi: 10.1159/000227607. [PMID: 9394845]
  • G Hudes. Estramustine-based chemotherapy. Seminars in urologic oncology. 1997 Feb; 15(1):13-9. doi: . [PMID: 9050135]
  • J Nakashima, M Sumitomo, A Miyajima, S Jitsukawa, M Murai. A transient increase in serum procollagen 1 carboxyterminal peptide following effective treatment in prostate cancer patients with bone metastases. Urologia internationalis. 1997; 58(4):236-8. doi: 10.1159/000282991. [PMID: 9253125]
  • E H Hernes, S D Fosså, S Vaage, P Ogreid, A Heilo, E Paus. Epirubicin combined with estramustine phosphate in hormone-resistant prostate cancer: a phase II study. British journal of cancer. 1997; 76(1):93-9. doi: 10.1038/bjc.1997.342. [PMID: 9218739]
  • M Baijal-Gupta, J E Fraser, M W Clarke, J W Xuan, M A Finkelman. A new scalable purification procedure for prostatic secretory protein (PSP94) from human seminal plasma. Protein expression and purification. 1996 Dec; 8(4):483-8. doi: 10.1006/prep.1996.0128. [PMID: 8954897]